Immunocore Holdings plc Announces 2024 Annual General Meeting Details

TL;DR

<b>Immunocore Holdings plc is holding its 2024 Annual General Meeting on May 23, 2024, as a hybrid event and urges shareholders to vote.</b>

AI Summary

Immunocore Holdings plc (IMCR) filed a Proxy Statement (DEF 14A) with the SEC on April 12, 2024. Immunocore Holdings plc will hold its 2024 Annual General Meeting (AGM) on May 23, 2024, at 2:30 p.m. London time. The AGM will be a hybrid meeting, allowing participation in person or electronically. The meeting will take place at the offices of Cooley (UK) LLP in London and virtually via meetnow.global/IHCAGM2024. Shareholders are urged to vote as soon as possible through the provided means. The filing is a Definitive Proxy Statement (DEF 14A) filed on April 12, 2024.

Why It Matters

For investors and stakeholders tracking Immunocore Holdings plc, this filing contains several important signals. This filing provides shareholders with crucial information and voting instructions for the upcoming AGM, impacting corporate governance and strategic decisions. The hybrid format aims to increase shareholder participation, allowing for broader engagement in company matters.

Risk Assessment

Risk Level: low — Immunocore Holdings plc shows low risk based on this filing. The filing is a routine proxy statement for an annual general meeting, with no immediate financial or operational risks indicated.

Analyst Insight

Shareholders should review the proxy statement and vote on the matters presented at the AGM to exercise their governance rights.

Key Numbers

• 2024 — Annual General Meeting Year (Year of the AGM)
• May 23 — AGM Date (Date of the AGM)
• 2:30 p.m. London time — AGM Time (Time of the AGM)
• 9:30 a.m. Eastern Daylight Time — AGM Time (EDT) (AGM time in Eastern Daylight Time)

Key Players & Entities

• Immunocore Holdings plc (company) — Registrant and filer of the proxy statement
• May 23, 2024 (date) — Date of the 2024 Annual General Meeting
• Cooley (UK) LLP (company) — Location for in-person participation at the AGM
• Professor Sir John Bell (person) — Chairman of Immunocore Holdings plc

FAQ

Risk Factors

• Filing Requirements [low — regulatory]: The company must comply with SEC regulations for proxy statements, including providing accurate and timely information to shareholders.

Industry Context

Immunocore Holdings plc operates in the biotechnology sector, focusing on developing novel cancer immunotherapies.

Regulatory Implications

The company is subject to SEC regulations governing proxy solicitations and shareholder communications, ensuring transparency and fair voting processes.

What Investors Should Do

1. Shareholders should review the proxy materials carefully before the AGM.
2. Vote on all proposed resolutions, including director elections and any other business.
3. Ensure voting instructions are submitted by the deadline to be counted.

Key Dates

• 2024-05-23: Annual General Meeting — Shareholder voting on company matters
• 2024-04-12: Filing Date — Definitive Proxy Statement filed

Glossary

DEF 14A

Definitive Proxy Statement filed with the SEC. (This filing provides official notice and details for the Annual General Meeting.)

AGM

Annual General Meeting of Shareholders. (Key event for shareholders to vote on company matters and governance.)

ADSs

American Depositary Shares. (Represents ownership in foreign company shares, relevant for voting procedures for certain shareholders.)

Year-Over-Year Comparison

This is the initial filing for the 2024 AGM, providing details on the upcoming meeting and voting procedures.

Filing Documents

• ny20024279x2_def14a.htm (DEF 14A) — 2740KB
• logo_cooley.jpg (GRAPHIC) — 25KB
• logo_immunocore.jpg (GRAPHIC) — 29KB
• ny20024279x2_barchart01.jpg (GRAPHIC) — 112KB
• ny20024279x2_linechart01.jpg (GRAPHIC) — 176KB
• ny20024279x2_pc01.jpg (GRAPHIC) — 1273KB
• ny20024279x2_pc02.jpg (GRAPHIC) — 914KB
• ny20024279x2_pvpchart01.jpg (GRAPHIC) — 200KB
• ny20024279x2_pvpchart02.jpg (GRAPHIC) — 176KB
• 0001140361-24-019623.txt (&nbsp;) — 11386KB
• imcr-20240523.xsd (EX-101.SCH) — 5KB
• imcr-20240523_def.xml (EX-101.DEF) — 6KB
• imcr-20240523_lab.xml (EX-101.LAB) — 11KB
• imcr-20240523_pre.xml (EX-101.PRE) — 5KB
• ny20024279x2_def14a_htm.xml (XML) — 247KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 33 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 35 DIRECTOR REMUNERATION 36 EXECUTIVE OFFICERS 38

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 39 PAY VERSUS PERFORMANCE 60 ADDITIONAL INFORMATION 63 ANNEX A A-1 ANNEX B B-1 1 TABLE OF CONTENTS QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING We have sent you this proxy statement and the enclosed form of proxy because the board of directors of Immunocore Holdings plc is soliciting your proxy to vote at our upcoming annual general meeting of shareholders (the "AGM"). As used in this proxy statement, references to "we," "us," "our" and "Immunocore" refer to Immunocore Holdings plc. The Notice of 2024 Annual General Meeting, this proxy statement, the form of proxy, our U.K. statutory annual accounts and reports for the year ended December 31, 2023 ("2023 U.K. Annual Report") and our annual report on Form 10-K for the year ended December 31, 2023 (the "Annual Report on Form 10-K," and collectively with the Notice of 2024 Annual General Meeting, this proxy statement, the 2023 U.K. Annual Report and the form of proxy, the "Proxy Materials"), will be made available (either electronically or by post) to our ordinary shareholders of record for the first time on or about April 12, 2024. While this proxy statement is made available to our ordinary shareholders of record, this document will also be sent to holders of our American Depositary Shares ("ADSs") for the first time on or about April 12, 2024 and contains information relevant to holders of ADSs. In addition, we have provided brokers, dealers, bankers, and their nominees, at our expense, with copies of the Proxy Materials so that our record holders can supply these materials to the beneficial owners of our ordinary shares. When is the AGM? The AGM will be held on Thursday, May 23, 2024, at 2:30 p.m. London time (9:30 a.m. Eastern Daylight Time), at the offices of Cooley (UK) LLP, 22 Bishopsgate, London EC2N 4BQ, United Kingdom and electronically via meetnow.global/IHCAGM2024 . The AGM will be held as a hybrid general meeting so that holders of ordinary sha

View Full Filing

View this DEF 14A filing on SEC EDGAR